{"links":{"feed":"https://www.erudio.com/reports/galahad-nct02854436/feed.json","html":"https://www.erudio.com/reports/galahad-nct02854436","json":"https://www.erudio.com/reports/galahad-nct02854436.json","markdown":"https://www.erudio.com/reports/galahad-nct02854436.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"galahad-nct02854436"}},"request":"https://www.erudio.com/contact?report=galahad-nct02854436"},"offer":{"cited_clinicians":12,"cited_commentary_sources":15,"verified_hcp_statements":272,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":16},"for_sale":true,"one_off_usd":1250,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or 3, 6 or 12 months of updates for your person; ask them for their work email and organization, both required. It returns the quote, a checkout_url for your person to pay by card and a pay_url your own payment client can pay over HTTP 402, with MPP (USDC on Tempo) or x402 (USDC on Base). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"required: the buyer's company or institution","product":["edition","updates-3","updates-6","updates-12"],"report":"galahad-nct02854436"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. Or pay it yourself: POST pay_url answers 402 Payment Required with both agent payment standards, MPP (USDC on Tempo) and x402 (USDC on Base); your payment client pays one. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=galahad-nct02854436","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/galahad-nct02854436","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"standard","size_line":"Standard · 272 verified statements · 95 from 12 confirmed clinicians","size_rule":"Standard: 151–300 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":{"3_months":2200,"6_months":3100,"12_months":4400},"volume_discounts":{"applies_to":"Update plans (updates-3, updates-6, updates-12) only. Never a single edition (product edition), however many an account buys.","rule":"Volume discounts apply to update plans only: 15% off a plan when one account has update plans on 5 or more trials, 25% off from 10 or more. A single edition is never discounted, however many an account buys, and there are no other discounts.","tiers":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]}},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-19T00:02:24.118230Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":14,"no_commentary_found":0},"aspects":[{"claim_count":6,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":4,"title":"Primary endpoint: Objective Response Rate (ORR) for Participants With Measurable Metastatic Castration-resistant Prostate Cancer (mCRPC) and Breast Cancer Gene (BRCA) Mutation"},{"claim_count":2,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":1,"title":"Secondary endpoints"},{"claim_count":11,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":6,"title":"Population and setting"},{"claim_count":12,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":7,"title":"The comparison"},{"claim_count":5,"coverage":"discussed","id":"T5","registry_field":"outcomesModule","source_count":5,"title":"Safety and tolerability"},{"claim_count":5,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":3,"title":"Design and conduct"},{"claim_count":67,"coverage":"discussed","id":"A1","source_count":9,"title":"Molecular selection, alteration type and testing access"},{"claim_count":18,"coverage":"discussed","id":"A2","source_count":9,"title":"Agent differentiation and time-specific regulatory context"},{"claim_count":35,"coverage":"discussed","id":"A3","source_count":5,"title":"Class safety, individualized management and delayed harms"},{"claim_count":16,"coverage":"discussed","id":"A4","source_count":4,"title":"Platinum alternatives, affordability and comparative evidence"},{"claim_count":41,"coverage":"discussed","id":"A5","source_count":4,"title":"Earlier combination choices and reasons to defer broader use"},{"claim_count":9,"coverage":"discussed","id":"A6","source_count":2,"title":"Response waiting, progression and subsequent treatment"},{"claim_count":9,"coverage":"discussed","id":"A7","source_count":1,"title":"Coexisting BRCA and MSI findings as an alternative-treatment question"},{"claim_count":23,"coverage":"discussed","id":"A8","source_count":5,"title":"Patient understanding, nursing support and genetic counseling"}],"counts":{"beyond_population_findings":7,"beyond_population_statements":201,"cited_clinicians":12,"cited_clinicians_by_role":{"nurse_practitioner":1,"physician":2,"physician, Medical oncology":8,"physician, Urology":1},"cited_physicians":11,"cited_sources":18,"claims_by_expression_type":{"comparison":18,"experience":31,"interpretation":58,"opinion":74,"primary_context":8,"question":23,"restatement":26,"uncertainty":17,"unspecified":17},"claims_by_kind":{"interpretation":2,"objective_result":3,"protocol_statement":4,"publication_statement":28,"source_observation":235},"clinician_statements":95,"evidence_units":167,"findings":10,"people_cited":20,"people_identity_verified":16,"people_total":21,"screened_sources":66,"verified_claims":272},"findings_index":[{"cited_clinicians":1,"id":"F1","structure":{"claims":20,"claims_by_group":{"comparisons":3,"experience":1,"questions":2,"restated":6,"views":8},"limitations":3,"links":{"context":6,"support":23},"ma_question":true,"named_voices":3,"passages":17,"sources":8,"sources_by_kind":{"commentary":2,"media":5,"publication":1}},"title":"GALAHAD by gene: what a speaker highlights in BRCA benefit and non-BRCA uncertainty","title_holders":{"cited_claim_ids":["claim-72d2a3d9ae9b56d544d6","claim-0784b89190489426317c","claim-342862b6c4f476dc1427","claim-1762c82975adb91c055c","claim-e6410f4fef772a235044","claim-f4dbfa08c958e265532c","claim-6957e4804ff35d7acc38","claim-2959c6c1201a4625f923","claim-ed09b7828b408e240b37","claim-0131bf5242f1c3549f86","claim-8a7833a5fe575df2cada","claim-118416b2b26a3144ef37"],"clinicians":false,"holders":1,"speakers":3,"view":"reading"},"evidence_line":"20 statements from 3 speakers in 8 sources, 5 of them podcasts or videos","holder_line":"1 of the 3 named speakers in this finding holds this view"},{"cited_clinicians":3,"id":"F2","structure":{"claims":20,"claims_by_group":{"comparisons":4,"experience":0,"questions":5,"restated":5,"views":6},"limitations":4,"links":{"context":5,"support":22},"ma_question":true,"named_voices":5,"passages":21,"sources":10,"sources_by_kind":{"commentary":2,"media":7,"publication":1}},"title":"PARP inhibitors: where speakers split on whether efficacy can be ranked","title_holders":{"cited_claim_ids":["claim-7c14f01c6d95e81af974","claim-7783cb2c913f9eb66262","claim-971b4fadde99bbc520a0","claim-b32bce4c153c2eb01ffa","claim-0abb246f9c5b87339c45","claim-af40785051d590fc4ec6","claim-c20f626025d38fe5241c","claim-5df7735d6c7c2d271a3c","claim-f4dbfa08c958e265532c","claim-a28495a17e34b6005af5"],"clinicians":false,"holders":3,"speakers":5,"view":"split"},"evidence_line":"20 statements from 5 speakers in 10 sources, 7 of them podcasts or videos","holder_line":"3 of the 5 named speakers in this finding take a side on this question"},{"cited_clinicians":0,"id":"F3","structure":{"claims":7,"claims_by_group":{"comparisons":2,"experience":0,"questions":0,"restated":2,"views":3},"limitations":3,"links":{"context":0,"support":9},"ma_question":true,"named_voices":0,"passages":6,"sources":2,"sources_by_kind":{"media":1,"publication":1}},"title":"Niraparib toxicity: a speaker describes it as class-consistent and highlights anemia","title_holders":{"cited_claim_ids":["claim-419c182b8d35b57bd2cf"],"clinicians":false,"holders":0,"speakers":0,"view":"reading"},"evidence_line":"7 statements in 2 sources, 1 of them a podcast or video","holder_line":"No named speaker is counted in this finding: its title's view comes from speakers the source does not name"},{"cited_clinicians":8,"id":"F4","population":"beyond","structure":{"claims":72,"claims_by_group":{"comparisons":1,"experience":9,"questions":9,"restated":14,"views":39},"limitations":4,"links":{"context":5,"support":79},"ma_question":true,"named_voices":12,"passages":49,"sources":10,"sources_by_kind":{"commentary":4,"media":5,"publication":1}},"title":"HRR testing: most speakers prioritize it; some see assay and prediction gaps","title_holders":{"caveat":{"among_lead":false,"cited_claim_ids":["claim-79364539909bfaa9093f","claim-773684b4b50c35d86093","claim-86faf05ae39660ac73c9","claim-3feb9b31bf70e4ead8e9","claim-e4fc290f25333ea5b589","claim-46566cf3112b04822017","claim-a440db8e2343d4bd1c59","claim-6675c0e3952ede70ae02","claim-18bed410053410fc9d75","claim-39d186596bd9f9abc537","claim-fdb736b506f0fa806b07","claim-af67a53f2921e2f4f593","claim-e732bda00ceb8cbfa5d5","claim-48d65978e4ca55515d48","claim-66e9339efc3ddee1c554","claim-87a1fb1a2a559bb3e653","claim-701b562f0b54c870aa5d","claim-ccd44404f3c94a6e7a1b","claim-504a21b23da3109acc1c","claim-7131a3f1de405f6c93c6","claim-0cb98960b2d9909bfd61"],"clause":"some see assay and prediction gaps","holders":6},"cited_claim_ids":["claim-773684b4b50c35d86093","claim-86faf05ae39660ac73c9","claim-3feb9b31bf70e4ead8e9","claim-46566cf3112b04822017","claim-ed4f6f0bad35e82f4ff5","claim-18bed410053410fc9d75","claim-fdb736b506f0fa806b07","claim-af67a53f2921e2f4f593","claim-e732bda00ceb8cbfa5d5","claim-29558b05b375a39ebff5","claim-c1fa572e298b0dbc6240","claim-18bc9cd36302b7c142c7","claim-41252c319dbcefa17ee9","claim-f156afc413cb474a8434","claim-b5c42c144d2c9afc926c","claim-1aaf084e5024ad229b14","claim-c5ab6c29cb085dab72a8","claim-8f30efdb989e6d7110ba","claim-ccd44404f3c94a6e7a1b","claim-e4bccd4ab0cfc2114d6c"],"clinicians":false,"holders":7,"speakers":12,"view":"reading"},"evidence_line":"72 statements from 12 speakers in 10 sources, 5 of them podcasts or videos","holder_line":"7 of the 12 named speakers in this finding hold this view; 6 of the 12 hold its caveat, “some see assay and prediction gaps”"},{"cited_clinicians":5,"id":"F5","population":"beyond","structure":{"claims":35,"claims_by_group":{"comparisons":1,"experience":5,"questions":8,"restated":6,"views":15},"limitations":4,"links":{"context":5,"support":40},"ma_question":true,"named_voices":8,"passages":31,"sources":5,"sources_by_kind":{"media":5}},"title":"PARP safety: how speakers weigh symptom control against long-term concerns","title_holders":{"cited_claim_ids":[],"clinicians":false,"holders":0,"sides":[{"cited_claim_ids":[],"holders":0},{"cited_claim_ids":[],"holders":0},{"cited_claim_ids":[],"holders":0}],"speakers":8,"view":"split"},"evidence_line":"35 statements from 8 speakers in 5 sources, all podcasts or videos","holder_line":"0 of the 8 named speakers in this finding take a side on this question: 0 on one side, 0 on the other"},{"cited_clinicians":3,"id":"F6","population":"beyond","structure":{"claims":16,"claims_by_group":{"comparisons":1,"experience":2,"questions":6,"restated":1,"views":6},"limitations":3,"links":{"context":5,"support":17},"ma_question":true,"named_voices":5,"passages":13,"sources":4,"sources_by_kind":{"commentary":1,"media":3}},"title":"Carboplatin: some speakers consider it if PARP access fails but lack head-to-head data","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-dec8ac09ef2c4720cff9","claim-71095f3def811506a6e8"],"clause":"lack head-to-head data","holders":2},"cited_claim_ids":["claim-436af6cfb30ccda28a0e","claim-af8be3ce725fd4001d3d","claim-dec8ac09ef2c4720cff9"],"clinicians":false,"holders":2,"speakers":5,"view":"reading"},"evidence_line":"16 statements from 5 speakers in 4 sources, 3 of them podcasts or videos","holder_line":"2 of the 5 named speakers in this finding hold this view; 2 of them hold its caveat, “lack head-to-head data”"},{"cited_clinicians":5,"id":"F7","population":"beyond","structure":{"claims":42,"claims_by_group":{"comparisons":4,"experience":2,"questions":6,"restated":4,"views":26},"limitations":4,"links":{"context":0,"support":45},"ma_question":true,"named_voices":6,"passages":30,"sources":5,"sources_by_kind":{"media":4,"publication":1}},"title":"1L mCRPC PARP combos: how speakers weigh biomarkers, prior therapy and access","title_holders":{"cited_claim_ids":["claim-f2d70cffef358a48217d","claim-33df4f62f39b9f1afcc9","claim-ceee259c05fcd7dbf1f0","claim-43e0793e219ad11d7fdb","claim-4879012360a5bfb5871d","claim-254337dea5237c210ccc","claim-bfcadec2a3da3fa0eab2","claim-6ddbe5ee839671a67c90","claim-73e56e5d7ea1b7d4d2c2","claim-5fe8174a098bebb63e77","claim-6bc14cbae695ac11d73c","claim-d91c88ebdf83384fe754","claim-009c2541fedbee40b021","claim-2086651fe478abb2c4c9","claim-e4cb2719dd8401c6745c","claim-a3f8754f15a9c9f50f26","claim-f6711258a33811d80947","claim-81814bb13404ea7260fe","claim-c3eca747262f7ae89721","claim-c52d559b4b5aea401038","claim-3e0ac4c1646b06ebec3a","claim-255979b1e40fbd80e1a7","claim-5e792dcfdca72da1f967","claim-c8a1ebb40cf6829c2aed","claim-e496297683494068d5d1","claim-002c5a980aa2030920e2","claim-108a73fa95c88c746cd6"],"clinicians":false,"holders":5,"speakers":6,"view":"split"},"evidence_line":"42 statements from 6 speakers in 5 sources, 4 of them podcasts or videos","holder_line":"5 of the 6 named speakers in this finding take a side on this question"},{"cited_clinicians":3,"id":"F8","population":"beyond","structure":{"claims":11,"claims_by_group":{"comparisons":0,"experience":1,"questions":3,"restated":0,"views":7},"limitations":3,"links":{"context":1,"support":11},"ma_question":true,"named_voices":3,"passages":10,"sources":3,"sources_by_kind":{"media":2,"publication":1}},"title":"PARP failure: what speakers say","evidence_line":"11 statements from 3 speakers in 3 sources, 2 of them podcasts or videos"},{"cited_clinicians":3,"id":"F9","population":"beyond","structure":{"claims":9,"claims_by_group":{"comparisons":0,"experience":2,"questions":1,"restated":1,"views":5},"limitations":4,"links":{"context":0,"support":9},"ma_question":true,"named_voices":3,"passages":4,"sources":1,"sources_by_kind":{"media":1}},"title":"BRCA-mutated, MSI-high prostate cancer: what speakers say","evidence_line":"9 statements from 3 speakers in 1 source, a podcast or video"},{"cited_clinicians":2,"id":"F10","population":"beyond","structure":{"claims":23,"claims_by_group":{"comparisons":0,"experience":9,"questions":0,"restated":1,"views":13},"limitations":3,"links":{"context":0,"support":24},"ma_question":true,"named_voices":5,"passages":12,"sources":5,"sources_by_kind":{"commentary":1,"media":4}},"title":"Molecularly informed prostate cancer care: most speakers support genetic counseling","title_holders":{"cited_claim_ids":["claim-17d976bb805a8f84f5ee","claim-0382b7612309c4213751","claim-7f8a555c226e6f620f35","claim-dcac1816e164cfdffe5e"],"clinicians":false,"holders":3,"speakers":5,"view":"reading"},"evidence_line":"23 statements from 5 speakers in 5 sources, 4 of them podcasts or videos","holder_line":"3 of the 5 named speakers in this finding hold this view"}],"open_question":{"basis":"From finding F1 (20 statements from 3 speakers in 8 sources)","cited_claim_ids":["claim-b43ca442098330c77321","claim-72d2a3d9ae9b56d544d6","claim-0784b89190489426317c","claim-342862b6c4f476dc1427","claim-1762c82975adb91c055c","claim-fb96a80f2ec362c42263","claim-e6410f4fef772a235044","claim-f4dbfa08c958e265532c","claim-6957e4804ff35d7acc38","claim-2959c6c1201a4625f923","claim-ed09b7828b408e240b37","claim-a2f519a8e9c86e35949f","claim-96defab6e14c311bfb6c","claim-0131bf5242f1c3549f86","claim-8a7833a5fe575df2cada","claim-4450799979409efe3839","claim-7a386ee3a69f6fa08c85"],"finding_ids":["F1"],"question":"What do clinicians still need to see on gene-specific responses to define niraparib monotherapy’s role beyond BRCA1/2 alterations in metastatic castration-resistant prostate cancer after androgen-signaling inhibitors and taxanes, particularly for ATM, CDK12 and rarer DNA-repair alterations?"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"Speakers read GALAHAD activity as strongest in BRCA-altered disease"},{"id":"section-2","level":2,"title":"Speakers question a secure ranking among PARP inhibitors"},{"id":"section-3","level":2,"title":"One speaker reads GALAHAD toxicity as class-consistent, with meaningful supportive-care needs"},{"id":"section-4","level":2,"title":"Beyond the trial population"},{"id":"section-5","level":3,"title":"Speakers prioritize molecular selection but leave important prediction and testing questions open"},{"id":"section-6","level":3,"title":"Speakers balance manageable symptoms against serious and delayed safety concerns"},{"id":"section-7","level":3,"title":"Speakers consider platinum when PARP-inhibitor access fails, while leaving the comparison unresolved"},{"id":"section-8","level":3,"title":"Speakers condition earlier combinations on treatment history and unresolved benefit–risk boundaries"},{"id":"section-9","level":3,"title":"Two speakers reject switching PARP inhibitors after failure while preserving other timing decisions"},{"id":"section-10","level":3,"title":"One speaker tentatively favors immunotherapy when BRCA2 and MSI-high coexist"},{"id":"section-11","level":3,"title":"One speaker emphasizes education and counseling alongside treatment opportunity"},{"id":"section-12","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, na, single group, phase2","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":6},{"id":"F2","shared_claims":1}],"id":"T1","label":"Primary endpoint: Objective Response Rate (ORR) for Participants With Measurable Metastatic Castration-resistant Prostate Cancer (mCRPC) and Breast Cancer Gene (BRCA) Mutation"},{"findings":[{"id":"F1","shared_claims":2}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":11}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":4},{"id":"F2","shared_claims":8}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F3","shared_claims":1}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":5}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-19T00:02:24.118230Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-19T00:19:07Z","record_hash":"c9b28637c607d148dffcc0a3626d5f3379e277e662b79120aaf6c17fbfb922cd","release_hash":"bb34f6aa728d2d4fd7240e480cee246d8c587720b781854a429bc49b32a1708f","report_id":"erudio-nct02854436","run_id":"2c4f5761-8f0b-4733-874f-712b599d88c5","schema_version":"5.0","slug":"galahad-nct02854436","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"Speakers interpret GALAHAD as supporting BRCA1/2-based selection because responses were less frequent with other alterations, with an explicit caution in discussion against inferring a survival improvement. Niraparib’s relative benefit drew tentative doubt in one discussion, whereas another speaker found no benefit-based reason to favor one PARP inhibitor over another. A medical oncologist requested comparative evidence; small groups with rarer alterations also leave their potential benefit uncertain.","examples":[{"claim_id":"claim-457d970a287afb536bd5","finding_id":"F2","identity_check":"staff_page","month":"2025-06","region":"ex-US","role":"Medical oncologist","source_type":"podcast","statement":"includes GALAHAD among the PARP-inhibitor monotherapy studies that provided the basis for current single-agent indications in prostate cancer."}],"meta_description":"66 sources screened · 272 verified statements (95 from clinicians verified by NPI or staff page) from 18 sources · 10 findings. Updated Nov 19, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-19T00:19:07Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":66},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","1 cited commentary passage leaves a source question open, such as who was speaking. The report attributes no further than the source shows.","Not yet captured in this edition: a view on assessment methods, mutation-defined benefit and survival uncertainty with PARP inhibition in metastatic castration-resistant prostate cancer; a view on biomarker selection and comparator choices for PARP-inhibitor treatment in DNA-repair–altered metastatic castration-resistant prostate cancer; a view on genetic testing, patient selection and evidence beyond scans when weighing PARP inhibition; a view on PARP inhibitor efficacy in BRCA-mutated metastatic castration-resistant prostate cancer; a view on having to defer treatment until castration resistance if approval is restricted to that setting; a view on assessment methods and mutation-specific evidence informing treatment selection in metastatic castration-resistant prostate cancer; a view on biomarker-guided selection and reasons to withhold PARP inhibition in metastatic castration-resistant prostate cancer; a view on how BRCA and other DNA-repair alterations qualify interpretation of progression and survival evidence; a view on interpreting PARP-inhibitor survival evidence in DNA-repair-altered metastatic castration-resistant prostate cancer when crossover occurs; a view on microsatellite instability work-up and immunotherapy selection in BRCA-mutated prostate cancer; a view on distinguishing pulmonary-only from liver metastases when assessing prognosis in metastatic castration-resistant prostate cancer.","2 passages in 1 source used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","259 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 18 sources about other trials or topics are not included.","ClinicalTrials.gov first posted results for the trial on 8 March 2022.","The sources reviewed include historical remarks from 2018 through June 2025. Approval, reimbursement, enrollment and anticipated-study statements retain their discussion timing and do not describe current universal availability.","This is a qualitative selection of public discussion, not a representative survey. A source count, repeated panel remarks, reposts or language versions cannot be treated as an independent-HCP count or a consensus measure.","Some passages do not identify their speakers sufficiently for named attribution. Their views remain attributed to their episodes or discussions rather than assigned from a program roster or neighboring remarks.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","Discussions without the trial name or using other wording may be absent. The material reviewed therefore cannot establish the complete public conversation about GALAHAD's clinical question.","Some relevant portions of the April 2023 episode remain incompletely assessed, including discussion of patient benefit beyond scans, testing, approval and treatment timing. Their absence may affect the balance of practical and patient-centered views.","Treatment-choice coverage is incomplete: the October 2022 webinar's concluding monotherapy-sequencing assessment and its treatment-history rationale are not fully represented, nor is a speaker's explanation of regional monotherapy approvals. This limits conclusions about preferred sequencing and the evidentiary reasons behind European and US differences.","The dose-reduction discussion captures a speaker's case-derived generalization, not a detailed patient-level toxicity course. It cannot quantify how often dose adjustment restores tolerability.","The full text of the separate GALAHAD quality-of-life publication was unavailable. Its abstract supports publication context but not a complete appraisal of that analysis or clinician uptake.","GALAHAD's nonrandomized cohort comparisons do not establish superiority over another treatment or a causal survival advantage. Cross-trial agent rankings and combination-dose explanations remain attributed, qualified opinions.","A talk described GALAHAD as involving roughly 50 patients; that is the speaker's approximate description, not the final study enrollment reported in the publication."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":5,"publication":2,"registry":1,"regulatory":0,"x_thread":8,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":15,"methods":1,"results":2},"count":18,"evidence_window":{"end":"2025-06-16","start":"2018-09-18"},"retrieval_snapshot":"2026-11-18T17:17:24.273355Z","timeline":[{"count":1,"week":"2018-W38"},{"count":1,"week":"2019-W35"},{"count":1,"week":"2020-W07"},{"count":1,"week":"2020-W14"},{"count":1,"week":"2020-W22"},{"count":1,"week":"2020-W31"},{"count":1,"week":"2020-W32"},{"count":1,"week":"2022-W05"},{"count":1,"week":"2022-W06"},{"count":1,"week":"2022-W14"},{"count":1,"week":"2022-W41"},{"count":1,"week":"2023-W14"},{"count":1,"week":"2023-W32"},{"count":2,"week":"2023-W49"},{"count":1,"week":"2025-W25"}],"undated_sources":3},"quote_policies":[{"id":"clinicaltrials:NCT02854436:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT02854436:results","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT02854436:context","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT02854436:protocol:1","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT02854436:sap:2","quote_policy":"short_quote_link_out"},{"id":"pubmed:35131040","quote_policy":"short_quote_link_out"},{"id":"pubmed:37404070","quote_policy":"short_quote_link_out"},{"id":"pubmed:40016438","quote_policy":"short_quote_link_out"},{"id":"openfda:b7f675e2-159c-490c-b6f4-3f16d9492b7d:20260728","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-4llrhdclvdlmmynkwsmg5tdc-3mczygyynst2k","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:6899314842147381249","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:004685","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:1821de","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:598a9f","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:941227","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:bd61c4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1042129756039217152:fc9e3309-d9e8-4d89-81ee-17a2dd28f533","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1056893937217085440:0a2c0ff0-9293-424b-97d7-c0c19356cbd6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1096031817591869445:528098b2-dd7f-432c-8097-f37afc597301","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1096033332494688259:6324d157-ba29-45a7-bcb4-c22dc3934eb4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1096085420629209091:bb92a461-1ba3-4920-aa03-6db1ed87de25","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1096450410414596096:02df818f-6185-4a1d-8454-09a659479a0b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1097506565727215616:e8f06ce4-f146-4a8c-a3c3-d7d62d62facb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1097811815768174596:5cc4aecb-08a5-4cd2-a83a-9304587296dc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1113998134169014273:43041165-40f6-41d5-a9eb-12f0a15c7cac","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1125771651386232832:99f29acf-05ce-4e27-ba19-a3e405fdb3a3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1167385145671868416:c3f53b47-e792-4a17-be2d-dab5f614c000","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1174488299387400192:b5658a7e-d204-49da-a4a8-656391f72903","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1178200091221471233:97ef1713-c7ca-42d3-a5fc-99e8fc417ed7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1178202157054599168:edb003dc-715a-4a03-968a-5454e14c3254","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1179325228503179264:7215eaaf-04e1-4a74-85c3-8e1eb0b21385","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1179931485773733892:958d9c13-f63e-441a-aa52-3b82d86dc808","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1180111235242762242:51d9e167-1d13-4977-b24c-44653feb652a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1180485324629331969:27bb1114-963b-44c6-b1e5-b11fdb52da9c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1180509652020277249:5ff252c4-1d0a-4271-88fe-258f35e5144d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1181076858475077632:54ce13eb-fcba-45fb-8801-32687ae1a77d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1223293707555950592:c51c81ae-1d6e-4e2f-835b-d2bd70f71989","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1223607077962207234:2c1c2033-e9f0-4897-a53e-147083553dca","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1228097698655539200:7f2b8fcb-c4db-4378-93b1-60a8874bad68","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1264771830734184449:f9744400-34b0-4d71-8816-211252844386","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1281574097990889472:9c7341e6-ee12-428c-ac26-544ff50ae77c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1289620593185153026:c9a4619b-c970-4523-b874-3c19185a47a9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1438563436913385473:8adf7d09-eaba-4c9f-a7b1-06318e3d1855","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1490015329996599296:10e52b7c-2df5-4b35-9c74-7fb07d79bde9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1490320904563347457:1b8369eb-cde4-4863-b80a-665b8ceff786","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1490612498751442945:0c3ed10f-34ad-4d07-a144-d0d7fec0b3f6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1491035003655917569:824e1f81-4691-4c50-af28-578558f1083f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1491049185612902401:facc431b-2cf0-4f28-8940-e1e51dbab8df","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1491070831253876736:56d547b2-5f34-41f3-b053-7565cba867cb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1491386513732550661:43978a8c-051d-46c8-ba04-5f45f4a1d690","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1492423038364798976:01d02e9a-fd64-42d5-831e-2d9c56585a9b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1499737407578591237:0069584c-8c81-46e5-87a8-031b46552314","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1500826099818938369:af514842-3884-43cb-87f8-26ba16a1fd4d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1503370901462650884:5b605e8c-2bb4-4095-ba87-29c0c1820bb8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1503420235092840452:6a6f60d2-c8cc-491e-925b-f833595f9a90","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1510195427718705154:5b1a0d51-8edf-4905-958a-16da083f2e2b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1512408855824805897:8e2a99f8-a29f-49b5-86d7-c4cc378770f9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1523807550809980928:195ea765-d5a4-4b25-b4d7-d03d0612e564","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1537012119455014914:7e652f57-61e2-4b0d-8160-644e67bdd1ca","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1537631150092558369:25eb7440-885f-4854-8736-192cfdf4a424","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1542180096873828354:0728dce1-ada6-4b56-9dd0-2d85420c3760","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1542976381893726209:1240acfd-7aa4-4fce-9575-afa3e94782dd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1543422160705933312:a558c4d0-9eb9-49bb-8c1b-2683a1128132","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1555614691233349634:e0f71a2f-f27a-4f7c-94a1-cfa1ffdfe502","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1565701195213201408:eab5092a-80b6-4139-87e5-470f80bd6a1a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1566433186586021888:e6f53926-add3-4ae3-b58a-1971e02e69cd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1567261948982738944:351bebd7-f443-4d67-b2da-caaa48e93af4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1704457565357109438:c9abbd17-db91-4748-a813-ea5532edfa79","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1797701122234138943:f2b30fe4-4a6e-45a1-b9a7-028d4f8eb80f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2050196063647150407:3491ceab-7ef7-4b78-b714-a3f8dd5db0de","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2106574860008968211:4035f0ae-9f51-422e-aebb-a11a3a6c54d8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:961674145988661248:38946838-e13b-4a46-8a7d-87b31271b4bd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_video:2078143630116577388","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:vx1QRItBcIo","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:yd3f2P0I0i4","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":1,"linkedin_post":1,"other":0,"podcast":5,"publication":0,"registry":0,"regulatory":0,"x_thread":56,"x_video":1,"youtube":2},"by_evidence_role":{"commentary":66},"count":66,"evidence_window":{"end":"2026-10-04","start":"2018-02-08"},"retrieval_snapshot":"2026-11-18T17:17:24.670908Z","timeline":[{"count":1,"week":"2018-W06"},{"count":1,"week":"2018-W38"},{"count":1,"week":"2018-W44"},{"count":4,"week":"2019-W07"},{"count":2,"week":"2019-W08"},{"count":1,"week":"2019-W14"},{"count":1,"week":"2019-W19"},{"count":1,"week":"2019-W35"},{"count":1,"week":"2019-W38"},{"count":2,"week":"2019-W39"},{"count":5,"week":"2019-W40"},{"count":1,"week":"2019-W41"},{"count":2,"week":"2020-W05"},{"count":1,"week":"2020-W07"},{"count":1,"week":"2020-W14"},{"count":1,"week":"2020-W22"},{"count":1,"week":"2020-W28"},{"count":1,"week":"2020-W31"},{"count":1,"week":"2020-W32"},{"count":1,"week":"2021-W37"},{"count":2,"week":"2022-W05"},{"count":6,"week":"2022-W06"},{"count":1,"week":"2022-W07"},{"count":1,"week":"2022-W09"},{"count":1,"week":"2022-W10"},{"count":2,"week":"2022-W11"},{"count":1,"week":"2022-W13"},{"count":1,"week":"2022-W14"},{"count":1,"week":"2022-W19"},{"count":2,"week":"2022-W24"},{"count":3,"week":"2022-W26"},{"count":1,"week":"2022-W31"},{"count":2,"week":"2022-W35"},{"count":1,"week":"2022-W36"},{"count":1,"week":"2022-W41"},{"count":1,"week":"2023-W14"},{"count":1,"week":"2023-W32"},{"count":1,"week":"2023-W38"},{"count":2,"week":"2023-W49"},{"count":1,"week":"2024-W23"},{"count":1,"week":"2025-W25"},{"count":1,"week":"2026-W04"},{"count":1,"week":"2026-W18"},{"count":1,"week":"2026-W29"},{"count":1,"week":"2026-W40"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":169,"publication":33,"registry":2,"regulatory":0,"x_thread":17,"x_video":0,"youtube":51}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"brand_names":["Zejula"],"label":"niraparib","slug":"niraparib"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Prostate cancer","slug":"prostate-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"GALAHAD","aliases":["GALAHAD","Galahad","An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies","A Phase 2 Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies"],"brief_title":"An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Prostatic Neoplasms"],"display_condition":"metastatic castration-resistant prostate cancer with DNA-repair gene defects","display_interventions":[["niraparib"]],"enrollment":{"count":289,"type":"ACTUAL"},"interventions":[{"name":"Niraparib","synonyms":["JNJ-64091742"],"type":"DRUG"}],"nct_id":"NCT02854436","official_title":"A Phase 2 Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies","overall_status":"COMPLETED","phase":["PHASE2"],"primary_completion_date":{"date":"2021-01-26","type":"ACTUAL"},"primary_endpoints":[{"description":"ORR defined as percentage of participants with BRCA DNA-repair anomalies and measurable disease whose best response is either complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and with no evidence of bone progression per Prostate Cancer Working Group 3 (PCWG3) criteria.","measure":"Objective Response Rate (ORR) for Participants With Measurable Metastatic Castration-resistant Prostate Cancer (mCRPC) and Breast Cancer Gene (BRCA) Mutation","timeFrame":"Up to 52 months"}],"registered_date":{"date":"2016-08-03","type":"ESTIMATED"},"registry_last_updated":"2025-12-22","registry_url":"https://clinicaltrials.gov/study/NCT02854436","short_name":"GALAHAD","short_name_basis":"canonical_name","sponsor":"Janssen Research & Development, LLC","start_date":{"date":"2016-08-31","type":"ACTUAL"},"study_design":"interventional, na, single group, phase2","study_ids":[{"id":"CR108208","type":"sponsor_study_id"},{"domain":"Janssen Research & Development, LLC","id":"64091742PCR2001","type":"other"},{"id":"2016-002057-38","type":"eudract_number"}],"study_type":"INTERVENTIONAL"}}}